ClinicalTrials.Veeva

Menu

Reduction of Foveal Sensitivity in Eyes With Diabetic Macular Edema

H

Hospital Juarez de Mexico

Status

Completed

Conditions

Clinically Significant Macular Edema
Diabetic Retinopathy

Study type

Observational

Funder types

Other

Identifiers

NCT01824862
HJM2021/11-B

Details and patient eligibility

About

Clinically significant macular edema (CSME) is a thickening of the macula associated with the risk of visual loss, which increases its centre is involved. Functional evaluation of the macula relies on best corrected visual acuity; however, neural dysfunction in diabetic eyes appears before retinal thickening and visual loss. Retinal sensitivity decreases in eyes with CSME, but it is unknown whether it differs between eyes with and without centre thickening.

Aim: To compare the reduction of foveal sensitivity in eyes with CSME, with and without centre thickening.

Full description

A non-experimental, comparative, prospective, cross-sectional study was conducted. Target population were type 2 diabetics, from Mexico City and its metropolitan area, and available population were type 2 diabetics who attended an Ophthalmology service from a general hospital in Mexico City, from September 2011 to May 2012.

Type 2 diabetic patients aged 30-85 years, from any gender, with central fixation, whose ocular media allowed obtaining an adequate quality Optical Coherence Tomography, who had CSME with focal angiographic pattern were included. Eyes with optic nerve or visual pathways diseases or any other ocular disease that decreased Best corrected visual acuity, were excluded. Diabetic patients without retinopathy who fulfilled the remaining selection criteria were evaluated as the reference group.

Sixty degrees colour fundus photographs were obtained in all the patients using a Visucam lite ocular fundus camera; in group 1 it was verified that no signs of diabetic retinopathy existed in the photographs; CSMO was diagnosed by biomicroscopy under mydryasis, according to the ETDRS criteria.

Retinal thickness was measured using Stratus optical coherence tomography (OCT), version 4.0.1 (Zeiss). The 6 mm fast macular map strategy was used, according to the following standardised operating procedure: mydriasis ≥6mm, inclusion of the spherical equivalent and anteroposterior axis, and optimisation of z axis and of polarisation; the photograph was taken with flash between 9:00 and 11:00, using an acquisition strategy for dark irises. The maps were obtained by the same investigator, independent from the one who evaluated the patients clinically; any deviation of the OCT line regarding the actual retina boundary was considered as a measurement error.

A 10° macular perimetry was obtained in all the patients, using a Humphrey field analyser model 750i (software version 4.1); the sixteen points evaluated were arbitrarily labelled. Retinal thickness within 3 mm from the centre of the fovea was measured in 9 fields, according to the fast macular map.

Enrollment

60 patients

Sex

All

Ages

30 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Type 2 diabetic patients
  • aged 30-85 years
  • from any gender
  • with central fixation
  • ocular media allowed obtaining an adequate quality Optical coherence tomography
  • CSME with focal angiographic pattern

Exclusion criteria

  • optic nerve or visual pathways diseases or any other ocular disease that decreased Best corrected visual acuity

Trial design

60 participants in 3 patient groups

eyes without diabetic retinopathy
Description:
eyes of patients with diabetes mellitus type 2 that does not have retinopathy
CSME without centre involvement
Description:
eyes with CSME without thickening in the 500 µm adjacent to the centre of the macula
CSME with centre involvement
Description:
eyes with CSME with thickening in the 500 µm adjacent to the centre of the macula

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems